ERBB2 and neoplasm: However, a number of HER2/NEU-positive tumours are not responsive to HER2/NEU-directed therapy (Menard et al, 2003; Hynes et al, 2005), indicating that other HER receptors as well as additional signalling molecules may influence the biological response to trastuzumab.